Physician profile
Rick L Jackson
NPI 1306983549
$27,986.74
in general payments reported to CMS, 2019-2025
48 companies · $1,955 in 2025
The $1,955 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,757 · 2020: $1,932 · 2021: $3,634 · 2022: $2,156 · 2023: $7,414 · 2024: $9,139 · 2025: $1,955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,400 · Food and Beverage: $6,055 · Consulting Fee: $1,823 · Travel and Lodging: $1,213 · Education: $18.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,400.00 |
| Food and Beverage | $6,055.09 |
| Consulting Fee | $1,822.50 |
| Travel and Lodging | $1,212.68 |
| Education | $18.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15,017.34 | 2019-2025 | Repatha, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,757.96 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,423.24 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $930.01 | 2019-2023 | Spravato |
| Kowa Pharmaceuticals America, INC. | $862.69 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Allergan, INC. | $809.65 | 2019-2021 | |
| Lilly USA, LLC | $797.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $695.10 | 2019-2024 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $601.55 | 2019-2024 | |
| Novo Nordisk INC | $485.36 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $443.46 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $406.65 | 2024-2025 | Zenpep, Vowst |
| Glaxosmithkline, LLC. | $374.17 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Lundbeck LLC | $324.37 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $320.96 | 2019-2025 | Eliquis, Camzyos |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rick Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.